SM 04646

Drug Profile

SM 04646

Alternative Names: SM-04646

Latest Information Update: 10 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Samumed
  • Class Antifibrotics; Small molecules
  • Mechanism of Action Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Idiopathic pulmonary fibrosis

Most Recent Events

  • 30 Jul 2018 Samumed LLC plans to initiate a phase II trial for Idiopathic pulmonary fibrosis (In adults, In the elderly) in Australia and New Zealand (Intranasal) (NCT03591926)
  • 24 Jul 2017 SM 04646 receives Orphan Drug status for Idiopathic pulmonary fibrosis in USA
  • 19 Jul 2017 Samumed completes a phase I trial in Idiopathic pulmonary fibrosis (In healthy volunteers) in Australia (Intranasal, Inhalant)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top